Vizient Joins CSRxP as 30th Member of the Coalition

csrxp

Vizient Joins CSRxP as
30th Member of Coalition

Today, Vizient, the nation’s largest member-driven health care performance improvement company, became the 30th member of the Campaign for Sustainable Rx Pricing (CSRxP). Vizient’s voice adds to a broad-based coalition of leaders working towards bipartisan, market-based solutions to the problem of out-of-control prescription drug prices, comprising physicians, nurses, hospitals, consumers, health plans, PBMs, pharmacists, and businesses.

“As an organization with members that span the health care delivery system, Vizient’s perspective on the harm done by out-of-control prescription drug prices is invaluable. We are exceptionally excited to welcome them as the 30th member of our Coalition, and look forward to working with them towards our goal of reining in prescription drug prices,” said CSRxP spokesman Will Holley.

“We are excited to join CSRxP and be a part of the coalition to achieve reasonable prescription drug prices,” says Jody Hatcher, president, sourcing and collaboration services at Vizient. “Our health care members are facing enormous financial and clinical pressures associated with pharmaceuticals. Rising drug prices are squeezing providers like never before. And Vizient is committed to being at the heart of finding solutions to these problems.”

###

About Vizient
Vizient, Inc., the largest member-driven health care performance improvement company in the country, provides innovative data-driven solutions, expertise and collaborative opportunities that lead to improved patient outcomes and lower costs. Vizient’s diverse membership base includes academic medical centers, pediatric facilities, community hospitals and non-acute health care providers.

About the Campaign for Sustainable Rx Pricing
The Campaign for Sustainable Rx Pricing (CSRxP) is a broad-based coalition of leaders – physicians, nurses, hospitals, consumers, health plans, PBMs, pharmacists, and businesses – promoting bipartisan, market-based solutions to lower drug prices in America.